Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival postprogression in the treatment of four types of cancer

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 3, 2015, Pages 1001-1006

  Liu, Li Ya ^a   Yu, Hao ^a   Bai, Jian Ling ^a   Zeng, Ping ^a   Miao, Dan Dan ^a   Chen, Feng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Overall survival; Progression free survival; Surrogate endpoint; Survival post progression

Indexed keywords

BIOLOGICAL MARKER;

CANCER STAGING; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; GLIOBLASTOMA; HUMAN; LUNG TUMOR; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; STATISTICAL MODEL; STOMACH TUMOR; SURVIVAL RATE;

BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; LUNG NEOPLASMS; MODELS, STATISTICAL; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84929332144     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.3.1001     Document Type: Article

References (28)

1. Alimujiang S, Zhang T, Han ZG, et al (2013). Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev, 14, 2413-9.
2. Booth CM, Eisenhauer EA (2012). Progression-Free Survival: Meaningful or Simply Measurable? J Clin Oncol, 30, 1030-3.
3. Bowater RJ, Bridge LJ, Lilford RJ (2008). The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. Cancer Lett, 262, 48-53.
4. Broglio KR, Berry DA (2009). Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst, 101, 1642-9.
5. Burzykowski T, Molenberghs G, Buyse M, et al (2001). Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C Appl Stat, 50, 405-22.
6. Buyse M, Sargent DJ, Grothey A, et al (2010). Biomarkers and surrogate end points[mdash]the challenge of statistical validation. Nat Rev Clin Oncol, 7, 309-17.
7. Cheema PK, Burkes RL (2013). Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. Curr Oncol, 20, 150-60.
8. Fleischer F, Gaschler-Markefski B, Bluhmki E (2009). A statistical model for the dependence between progression-free survival and overall survival. Stat Med, 28, 2669-86.
9. Fu H, Wang Y, Liu J, et al (2013). Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model. Stat Med, 32, 240-54.
10. Giessen C, Laubender RP, Ankerst DP, et al (2013). Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res, 19, 225-35.
11. Hall P, Martin MA (1989). A note on the accuracy of bootstrap percentile method confidence intervals for a quantile. Stat Probabil Lett, 8, 197-200.
12. Han K, Ren M, Wick W, et al (2014). Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol, 16, 696-706.
13. Hayashi H, Okamoto I, Morita S, et al (2012). Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol, 23, 1537-41.
14. Hayashi H, Okamoto I, Taguri M, et al (2013). Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer, 14, 261-6.
15. Kawakami H, Okamoto I, Hayashi H, et al (2013). Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. Eur J Cancer, 49, 3003-9.
16. Lima JPdSN, Santos LVd, Sasse EC, et al (2009). Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis. Eur J Cancer, 45, 601-7.
17. Michael JR, Schucany WR (2002). The mixture approach for simulating bivariate distributions with specified correlations. Am Stat, 56, 48-54.
18. Mok TSK (2011). Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol, 8, 661-8.
19. Paoletti X, Oba K, Bang YJ, et al (2013). Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst, 105, 1667-70.
20. Petrelli F, Barni S (2013). Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies. Clin Genitourin Cancer, 11, 385-9.
21. Saad ED, Katz A, Buyse M (2010a). Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol, 28, 1958-62.
22. Saad ED, Katz A, Hoff PM, et al (2010b). Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol, 21, 7-12.
23. Shi Q, Renfro LA, Bot BM, et al (2011). Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. Comput Stat Data An, 55, 2748-57.
24. Shitara K, Matsuo K, Muro K, et al (2013). Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J Cancer Res Clin Oncol, 139, 1383-9.
25. Soria JC, Massard C, Le Chevalier T (2010). Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol, 21, 2324-32.
26. Sridhara R, Johnson JR, Justice R, et al (2010). Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst, 102, 230-43.
27. Sundar S, Wu J, Hillaby K, et al (2012). A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecol Oncol, 125, 493-9.
28. Team RC (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.